HBV viral load < 10 IU/mL | Univariate analysis | Multivariate analysis | ||||||
---|---|---|---|---|---|---|---|---|
n | (%) | OR | 95% CI | p | Adjusted OR | 95% CI | p | |
School educational level | ||||||||
Lower than secondary | 34 | (63.0%) | 1.00 | 1.00 | ||||
Secondary or higher | 80 | (77.7%) | 2.04 | 0.97–4.27 | 0.058 | 2.31 | 1.05–5.07 | 0.037 |
CD4 cell count (per 100 cells/mm3 increase) | 1.19 | 1.01–1.41 | 0.033 | |||||
HIV viral load (copies/mL) | ||||||||
≥ 300 | 20 | (54.1%) | 1.00 | 1.00 | ||||
< 300 | 94 | (78.3%) | 3.26 | 1.42–7.46 | 0.005 | 3.46 | 1.48–8.09 | 0.004 |
ALT level (per 10 IU/L increase) | 0.91 | 0.81–1.02 | 0.111 | 0.86 | 0.75–0.97 | 0.019 | ||
AST level (per 10 IU/L increase) | 0.86 | 0.75–0.99 | 0.033 | |||||
Time since ART initiation (per 5-year increase) | 2.44 | 1.11–5.34 | 0.025 | |||||
Duration of 3TC/FTC monotherapy (per 1-year increase) | 1.18 | 1.01–1.36 | 0.042 | |||||
Adherence to ART in the previous 4 weeks | ||||||||
Perfect adherence | 26 | (59.9%) | 1.00 | |||||
Adherence difficultiesa | 60 | (76.9%) | 2.40 | 1.04–5.52 | 0.039 | |||
Treatment interruption more than 2 consecutive days | 28 | (80.0%) | 2.83 | 0.97–8.21 | 0.055 | |||
Region of study hospital | ||||||||
Centre | 74 | (76.3%) | 1.00 | |||||
Littoral | 40 | (66.7%) | 0.58 | 0.25–1.35 | 0.206 | 0.42 | 0.19–0.96 | 0.039 |
Type of HIV service | ||||||||
Primary | 55 | (64.7%) | 1.00 | 1.00 | ||||
Secondary | 59 | (81.9%) | 2.47 | 1.17–5.22 | 0.017 | 2.79 | 1.24–6.27 | 0.013 |